Standard BioTools Inc.
LABHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Standard BioTools Inc. focuses on Medical Devices services and products. Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop. At a $271.7M market cap, Standard BioTools Inc. ranks as a micro-cap company within healthcare. The company operates through Proteomics and Genomics segments.
Market Cap
$271.7M
Beta
1.37
P/E (TTM)
—
P/E (Fwd)
-69.20
EPS (TTM)
$-0.13
EPS (Fwd)
$-0.01
ROE
-11.2%
ROA
-6.6%
Cash
$476.7M
Total Debt
$28.1M
Free CF
$176.6M
52W Change
-46.1%
Annual Financials
Cash vs Debt
Where LAB stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LAB finished 28.72% below its 150-day moving average ($0.94) and 37.38% below its 200-day moving average ($1.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LAB overbought or oversold?
At the September 3, 2026 close, LAB's RSI(14) was 31.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $476.7M in cash and $28.1M in debt, LAB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $176.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -11.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $97.9M (2022) to $85.3M (2025), a 13% decline worth watching.
With cash comfortably exceeding debt, LAB has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Standard BioTools Inc. and its sector.